REIMBURSEMENT FOR CLINICAL laboratory testing has declined, particularly for molecular tests. As a consequence, the nation’s two largest laboratory testing companies are feeling the negative effect of lower lab test prices. Both Quest Diagnostics Incorporated and Laboratory Corporation of America issued their third quarter earnings reports last week. Their respective performances provide insights into several […]
- "Dark Index"
Two Blood Brothers Report Declines in Revenue-Per-Req
Expect the next bitter market share battle to involve BRCA testing as national labs push their BRCA tests
- By Joseph Burns
- > From the Volume XX No.14 - October 21, 2013 Issue
- Tags: brca test, brca testing, brca tests, clinical lab, Clinical Laboratory, clinical laboratory test, clinical laboratory testing, days sales outstanding, dso, impac, lab manager, lab managers, lab test, lab test prices, laboratory companies, laboratory test, laboratory testing, laboratory testing companies, Medicare, molecular pathology, molecular testing, molecular tests, myriad genetic, myriad genetics, outreach lab, pathologists, patient billing, quest diagnostics and labcorp, the laboratory
